Murali K. Prahalad, Ph.D. – President and CEO
Dr. Prahalad brings over eighteen years of executive and entrepreneurial experience in the life sciences industry. Prior to joining Iridia, he served as President and CEO of Epic Sciences, Inc. (EPIC), a venture backed company that builds predictive, blood-based tests of drug response in cancer. While at Epic, Dr. Prahalad helped advance the company’s functional cell profiling technology platform, develop, launch and obtain Medicare reimbursement for its leading test in metastatic prostate cancer and raise over $128M in venture financing. Prior to Epic, Dr. Prahalad also held various roles at Life Technologies Corporation, a global leader in reagents and instruments for biomedical research. His final role at Life Technologies was VP, Corporate Strategy which culminated in the strategic sale of Life Technologies to ThermoFisher Scientific (NYSE: TMO) in 2013 for $15.5B – the largest non-pharmaceutical acquisition in the biotechnology space. Prior to Life Technologies, Dr. Prahalad was VP of Business Development for Sequenom, Inc., a pioneer in blood-based, pre-natal diagnostics. Dr. Prahalad received his B.Sc. with Honors from the University of Michigan and Doctorate in Biochemistry & Molecular Pharmacology from Harvard University.
Paul Predki, Ph.D. – Chief Technology Officer and Head of Research
Dr. Paul Predki served as Vice President for Molecular & Protein Biology R&D at Life Technologies where he joined as part of the acquisition of Protometrix in 2004, a protein microarray company he helped start in 2001 as a spin-out from Yale University. Prior to that he served as Associate Director at the DOE Joint Genome Institute, where he was responsible for the development and implementation of the Institute’s high-throughput production sequencing and genomics programs. Dr. Predki also spent four years at CuraGen Corporation. Dr. Predki did his post-doctoral training at Yale University, where he investigated protein engineering and protein biochemistry. He obtained his Ph.D. in Biochemistry from the University of Toronto. Dr. Predki has published in a variety of high-profile journals, including Science, Nature and Cell.
Stefen A. Boehme, PhD – Director of Molecular Technologies
Dr. Stefen Boehme has over 20 years of experience in the biotech and biopharma industry and has been involved in the development of multiple therapeutics for inflammatory and allergic diseases. Most recently at Axikin Pharmaceuticals, he used his expertise in molecular biology, protein engineering and enzymology to successfully advance several early stage programs through Phase I & II clinical trials. Dr. Boehme did his post-doctoral training at the National Institutes of Health, and his Ph.D. in Molecular Immunology at the University of Florida. Dr. Boehme has authored 38 research publications and one patent.